Ixekizumab Plaque Psoriasis Treatment
In March 2016, the FDA approved a new medication called ixekizumab (under the brand name Taltz) for the treatment of psoriatic arthritis and moderate-to-severe cases of plaque psoriasis. Ixekizumab is a biologic drug taken intravenously via injections. Biologic drugs are manufactured using living organisms in the lab.
This biologic drug is approved to be used in the treatment of those who have had no success with standard topical therapies and may be combined with the use of phototherapy. Ixekizumab is classified as a systemic medication and relieves the symptoms of plaque psoriasis by targeting the immune system response that causes inflammation. Ixekizumab as a form of maintenance therapy needs to be used continuously for optimal results as plaque psoriasis is chronic and recurrent by nature.